Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized double-blind trial of fesoterodine versus placebo and tolterodine ER in overactive bladder
2006-006935-38Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fesoterodine in overactive bladder (OAB) (3 arms), sponsored by Pfizer. Primary endpoint: Change in urgency urinary incontinence episodes at 12 weeks. Started Feb 2007; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2006-006935-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006935-38.